The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Mechanism of action of the novel KRASG12C inhibitor GDC-6036
Adrian Sacher, MD, Princess Margaret Cancer Centre, Toronto, Canada, explains the mechanism of action of the novel KRASG12C KRAS inhibitor GDC-6036, which binds to and locks KRAS in an inactive state to prevent further KRAS downstream signaling. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript
GDC-6036 is a novel KRASG12C inhibitor. It works by binding to an essentially locking KRASG12C into an inactive state. As a result, it prevents further downstream KRS signaling. What’s unique about GDC6036 is that it is more selective and potent than previous KRASG12C, hence all the promise and interest in it.
GDC-6036 is a novel KRASG12C inhibitor. It works by binding to an essentially locking KRASG12C into an inactive state. As a result, it prevents further downstream KRS signaling. What’s unique about GDC6036 is that it is more selective and potent than previous KRASG12C, hence all the promise and interest in it.
Read more...
